2016 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2015 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
2009 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2008 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
Total Project Funding: | > 1000 |
Partner Constancy: | > 1000 |
Project Leadership Index: | > 1000 |
Diversity Index: | > 1000 |
2007 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
Total Project Funding: | > 1000 |
Partner Constancy: | > 1000 |
Project Leadership Index: | > 1000 |
Diversity Index: | > 1000 |
Total number of projects: 4
As coordinator: 0
As participant: 4
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2017 | 0 | 5.979.607 | 136.000 | 1 | ||
2015 | 0 | 18.200.000 | 0 | 1 | ||
2013 | 0 | 8.999.969 | 303.450 | 1 | ||
2012 | 0 | 5.976.298 | 398.420 | 1 |
Total number of partners: 107
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 107
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2017-01-01 | Crimean-Congo Haemorrhagic Fever Vaccine | CCHFVaccine | participant | 5.979.607 | 14 |
2015-01-01 | TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development | TBVAC2020 | participant | 18.200.000 | 44 |
2013-03-01 | Integrated Approaches to Food Allergen and Allergy Risk Management | IFAAM | participant | 8.999.969 | 38 |
2012-11-01 | "Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)" | TARGETAMD | participant | 5.976.298 | 15 |